Atossa Therapeutics appoints Claudia Lopez as VP, clinical development

Atossa Therapeutics (ATOS) announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial design, and regulatory alignment. In her new role at Atossa, Dr. Lopez will focus on advancing Atossa’s clinical pipeline, contributing to the development and delivery of next-generation cancer treatments.